EATRIS and EUPATI sign collaboration agreement, ensuring stronger patient training in translational research
The European Infrastructure for Translational Medicine (EATRIS) and the European Patients’ Academy on Therapeutic Innovation (EUPATI) have signed a partnership agreement, demonstrating both organisations’ commitment to provide education and training opportunities in translational research for patient advocates and strengthen academic researchers’ capacities to effectively engage with patients in their research.
Supported by 13 EU Member States, EATRIS’ mission is to accelerate the translation of discoveries into patient benefit. In 2018 EATRIS made patient involvement a key priority of its 2019-2022 Strategic Agenda to support effective multi-stakeholder collaboration and a genuine patient-centered approach throughout the translational science process. Patient engagement is also a key objective of EATRIS-Plus, a 4-year H2020 flagship initiative for personalised medicine, which will run until 2023.
EUPATI is a multi-stakeholder public-private partnership originally established by the IMI-EUPATI project (2012-2017) and now hosted by the European Patients Forum (EPF). It provides education and training to increase the capacity and capability of patients and patient representatives to understand and meaningfully contribute to medicines research and development, and to improve the availability of medical information for patients and other stakeholders.
EPF and EATRIS have collaborated since 2019 to raise awareness, train and incentivise translational researchers to adopt responsible research principles and involve patients and patient organisations as co-partners in research. EPF is also a project partner in the EATRIS-Plus project and is responsible for driving patient engagement related activities.
Toni Andreu (MD, PhD), EATRIS Scientific Director, said: “By expanding this collaboration, EATRIS and EUPATI take further concrete steps towards bridging the gap between patients and researchers, which will lead to more effective patient engagement in earlier phases of the medicines’ life cycle.”
Maria Dutarte, EUPATI Coordinator, said: “This collaboration will provide patients and patient representatives with increased knowledge about the area of translational medicine and strengthen their engagement in research.”
To kick-off this collaboration, EATRIS will become a public partner of EUPATI and welcome patient advocates at the next edition of its yearly training course, TMex – Translational Medicine Explained, a 5-day introduction to translational research.
By expanding this collaboration, EATRIS and EUPATI take further concrete steps towards bridging the gap between patients and researchers, which will lead to more effective patient engagement in earlier phases of the medicines’ life cycle.
This collaboration will provide patients and patient representatives with increased knowledge about the area of translational medicine and strengthen their engagement in research.